IP Library Patent Application 12041976
Patent Application
App. No. 12/041,976

STATIN COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/041,976
Abstract

The present invention relates to an improved statin or salt thereof composition, especially an atorvastatin composition, which exhibits enhanced dissolution properties in acidic media. It comprises a statin active ingredient and an aminoalkyl methacrylate copolymer dispersed therein, such as dimethyl aminoethyl methacrylate. The invention also relates to a process for preparing the improved composition and to methods of using it for the treatment of dyslipidemia.

Claims (25)

1 . A statin or salt thereof composition having a dissolution, for a composition containing 80 mg of equivalent statin, in a 1000 ml USP HCl buffer at pH 2.2, using the paddles method at 75 rpm, of at least 40% at 10 minutes, at least 50% at 20 minutes and at least 60% at 60 minutes.

2 . The composition of claim 1 having a dissolution in a 1000 ml USP HCl buffer at pH 2.2, using the paddles method at 75 rpm, of at least 60% at 10 minutes, at least 70% at 20 minutes and at least 80% at 60 minutes.

3 . The composition of claim 1 , comprising between 10 and 40% of statin.

4 . The composition of claim 1 , wherein the statin is at least one ring-opened 7-substituted-3,5-dihydroxyheptanoic acid or ring-opened 7-substituted-3,5-dihydroxyheptenoic acid.

5 . The composition of claim 1 , wherein the statin is selected from the group consisting of lovastatin, mevastatin, simvastatin, pravastatin, atorvastatin, cerivastatin, itavastatin, fluvastatin, pitavastatin, rosuvastatin, and salts thereof.

6 . The composition of claim 1 , wherein the statin is under a salt form.

7 . The composition of claim 1 , under a tablet form.

8 . The composition of claim 1 , wherein the statin or salt thereof is atorvastatin.

9 . The composition of claim 2 , wherein the statin or salt thereof is atorvastatin.

10 . The composition of claim 8 , under a tablet form.

11 . A statin or salt thereof composition comprising at least one aminoalkyl methacrylate copolymer dispersed therein.

12 . The composition of claim 11 , wherein the aminoalkyl methacrylate copolymer is dimethyl aminoethyl methacrylate.

13 . The composition of claim 11 , comprising between 10 and 50 wt % of aminoalkyl methacrylate copolymer.

14 . The composition of claim 11 , comprising between 20 and 40 wt % of aminoalkyl methacrylate copolymer.

15 . The composition of claim 11 , comprising between 10 and 40% of statin.

16 . The composition of claim 11 , wherein the statin is at least one ring-opened 7-substituted-3,5-dihydroxyheptanoic acid or ring-opened 7-substituted-3,5-dihydroxyheptenoic acid.

17 . The composition of claim 11 , wherein the statin is selected from the group consisting of lovastatin, mevastatin, simvastatin, pravastatin, atorvastatin, cerivastatin, itavastatin, fluvastatin, pitavastatin, rosuvastatin, and salts thereof.

18 . The composition of claim 11 , wherein the statin is under a salt form.

19 . The composition of claim 11 , under a tablet form.

20 . The composition of claim 11 , wherein the statin or salt thereof is atorvastatin.

21 . The composition of claim 20 , comprising between 10 and 40% of atorvastatin.

22 . The composition of claim 20 , under a tablet form.

23 . A method for the treatment of dyslipidemia, comprising the step of orally administering to a patient in need of such treatment a therapeutically effective unit dosage of a statin or salt thereof composition comprising at least one aminoalkyl methacrylate copolymer dispersed therein.

24 . A method for the treatment of dyslipidemia, comprising the step of orally administering to a patient in need of such treatment a therapeutically effective unit dosage of statin or salt thereof composition having a dissolution, for a composition containing 80 mg of equivalent statin, in a 1000 ml USP HCl buffer at pH 2.2, using the paddles method at 75 rpm, of at least 40% at 10 minutes, at least 50% at 20 minutes and at least 60% at 60 minutes.

25 . A method for the manufacture of a statin composition, comprising the steps of (i) preparing a granule comprising a statin and at least one aminoalkyl methacrylate copolymer mixed therewith, and (ii) compressing the resulting granule into a tablet.

Assignments (6)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Apr 23, 2021
From: ALTER DOMUS (US) LLC (SUCCESSOR TO MORGAN STANLEY SENIOR FUNDING, INC.)
To: KREMERS URBAN PHARMACEUTICALS INC.; CODY LABORATORIES, INC.
Reel/Frame 056031/0185 →
SECURITY INTEREST Recorded Dec 7, 2020
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
Reel/Frame 054566/0585 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 30, 2015
From: KREMERS URBAN PHARMACEUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 037171/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2014
From: KUDCO IRELAND LIMITED
To: KREMERS URBAN PHARMACEUTICALS INC.
Reel/Frame 034077/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2014
From: PHARMA PASS II, LLC
To: KUDCO IRELAND LIMITED
Reel/Frame 032764/0902 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2008
From: SCHMITT, BENOIT; IMLER, LAURENT
To: PHARMA PASS II LLC
Reel/Frame 020932/0419 →